NEW ASPECTS OF TREATMENT OF CHRONIC HEART FAILURE: FOCUS ON ANTAGONISTS OF MINERALOCORTICOID RECEPTORS
Introduction. The article presents evidence of the efficacy and safety of the use of receptor blockers aldosterone, which were obtained in the implementation of several randomized clinical trials. Presents the first experience of application of the selective antagonist of mineralocorticoid receptors in clinical practice.
The aim of the study was to assess the effect of the antagonist of mineralocorticoid receptors of eplerenone on the functional state of patients with heart failure, dynamics of the LV ejection fraction and the concentration of brain natriuretic peptide in the blood.
Results and conclusions: the study included 21 men (70%) and 9 women (30%) the average age of the patients was 57,9 ± 3,3 years. All patients had a detailed clinical picture of heart failure, functional class NYHA of CHF were III (56%) and IV (44%). In the primary analysis of the data of echocardiography, the average left ventricular ejection fraction was 37,5 ± 2,7 per cent. Brain natriuretic peptide (BNP) were determined selectively, examinees was average BNP – 475,7 ± 3,9 pg/ml. At the control examination, the average LVEF was 45,4 ± 1,5%, and the average creatinine and potassium was 108 ± 2,1 mcmol/l and 5,2 ± 0,9 mmol/l respectively.
Conclusion: AMS is an obligatory component of therapy of CHF. Eplerenone showed its effectiveness in improving functional status, increasing LV EF in patients with CHF decompensation.
Key words: heart failure, antagonist of mineralocorticoid receptors, ejection fraction.
Bibliography link
Karazhanova L.K., Nasymbekov M.R., Khaidarova O.V., Orekhov A.Yu., Ospanova M.M. New aspects of treatment of chronic heart failure: focus on antagonists of mineralocorticoid receptors. Nauka i Zdravookhranenie [Science & Healthcare]. 2017, 6, pp. 88-100.